CT1194C for patients with relapsed or refractory B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new treatment called CT1194C for patients with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two previous treatments. It aims to see if this treatment can help control the lymphoma and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with B-cell non-Hodgkin lymphoma that has returned or hasn't improved after at least two prior treatments.
- You have measurable disease (tumors that can be seen on scans or exams).
- You are not pregnant or breastfeeding, and you agree to use effective birth control for 1 year after treatment if applicable.
- You have no serious infections like HIV, active hepatitis B or C, or syphilis.
- You have not had major surgery or certain treatments within 2-4 weeks before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
This study tests a new cancer treatment called CT1190B for people with certain types of B-cell lymphoma that have not responded to or came back after other treatments. The goal is to see if it can help shrink or control the lymphoma.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new type of cell therapy called CT1194D for people with certain B-cell blood cancers that have not responded to or have come back after standard treatment. The therapy is designed to find and destroy cancer cells that carry the CD19 or CD20 marker.
This trial tests an experimental therapy called CT1195E, a type of 'living drug' made from your own immune cells to fight B-cell cancers that have returned or not responded to standard care. It's a phase 1 study, which means the main goal is to find a safe and effective dose, but you may benefit from the treatment.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.